[
  {
    "ts": null,
    "headline": "Is Incyte (INCY) Still Attractively Priced After Its Strong 1 Year Share Price Gain?",
    "summary": "If you are wondering whether Incyte's share price still offers value after its recent run, you are not alone. The stock closed at US$103.43 recently, with a 3% decline over the last 7 days, an 8.4% gain over 30 days, 2.0% year to date, 43.8% over 1 year and 10.1% over 5 years. This performance has many investors reassessing both opportunity and risk. Recent coverage has focused on how Incyte fits into the broader pharmaceuticals and biotech space, including ongoing interest in its product...",
    "url": "https://finnhub.io/api/news?id=2cd7f8f1b1a757c9ba77175388b442817e1814a18119562748369b5bd6aa249c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768388924,
      "headline": "Is Incyte (INCY) Still Attractively Priced After Its Strong 1 Year Share Price Gain?",
      "id": 138110595,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "If you are wondering whether Incyte's share price still offers value after its recent run, you are not alone. The stock closed at US$103.43 recently, with a 3% decline over the last 7 days, an 8.4% gain over 30 days, 2.0% year to date, 43.8% over 1 year and 10.1% over 5 years. This performance has many investors reassessing both opportunity and risk. Recent coverage has focused on how Incyte fits into the broader pharmaceuticals and biotech space, including ongoing interest in its product...",
      "url": "https://finnhub.io/api/news?id=2cd7f8f1b1a757c9ba77175388b442817e1814a18119562748369b5bd6aa249c"
    }
  }
]